Abdominal radiology (New York) · 2026
MRI-derived visceral adipose tissue quantification enhances stratification of nonalcoholic steatohepatitis severity and fibrosis in obesity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Xin, Li Ying-Long, Feng You-Zhen, Cheng Zhong-Yuan, Sun Bin, Cai Xiang-Ran
Аннотация
PURPOSE: Visceral adiposity is a key factor in the development of nonalcoholic steatohepatitis (NASH), yet its quantitative relationship with fibrotic progression remains inadequately characterized. This study aimed to assess the diagnostic performance of MRI-derived visceral fat content (VFC) for stratifying NASH severity and fibrosis in obese individuals.
METHODS: In this retrospective, single-center study, 138 obese patients (body mass index ≥ 30 kg/m²) who underwent liver biopsy and chemical shift-encoded MRI (iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantitation (IDEAL-IQ)) between April 2020 and September 2022 were included. Fibrotic NASH (Fibro-NASH) was defined histologically as a NAFLD activity score (NAS) ≥ 4 and fibrosis stage ≥ 2. MRI-derived metrics, including VFC and visceral fat area (VFA), were compared between groups. Multivariable logistic regression and receiver operating characteristic (ROC) analyses were performed.
RESULTS: Patients with Fibro-NASH had significantly lower median VFC compared to those without Fibro-NASH (P < 0.001). VFC was identified as an independent predictor of Fibro-NASH (odds ratio (OR) = 0.51, 95% CI: 0.26-0.97). A model combining VFC, muscle fat content, and aspartate aminotransferase exhibited the highest predictive accuracy for Fibro-NASH (AUC = 0.89; 95% CI, 0.80-0.97), outperforming models using VFA and VFC alone (both P < 0.05).
CONCLUSION: MRI-derived VFC represents a promising, noninvasive biomarker for assessing NASH severity and its progression to Fibro-NASH in obesity. Integrating VFC into clinical practice may enhance risk stratification and facilitate timely interventions for advanced liver disease.
METHODS: In this retrospective, single-center study, 138 obese patients (body mass index ≥ 30 kg/m²) who underwent liver biopsy and chemical shift-encoded MRI (iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantitation (IDEAL-IQ)) between April 2020 and September 2022 were included. Fibrotic NASH (Fibro-NASH) was defined histologically as a NAFLD activity score (NAS) ≥ 4 and fibrosis stage ≥ 2. MRI-derived metrics, including VFC and visceral fat area (VFA), were compared between groups. Multivariable logistic regression and receiver operating characteristic (ROC) analyses were performed.
RESULTS: Patients with Fibro-NASH had significantly lower median VFC compared to those without Fibro-NASH (P < 0.001). VFC was identified as an independent predictor of Fibro-NASH (odds ratio (OR) = 0.51, 95% CI: 0.26-0.97). A model combining VFC, muscle fat content, and aspartate aminotransferase exhibited the highest predictive accuracy for Fibro-NASH (AUC = 0.89; 95% CI, 0.80-0.97), outperforming models using VFA and VFC alone (both P < 0.05).
CONCLUSION: MRI-derived VFC represents a promising, noninvasive biomarker for assessing NASH severity and its progression to Fibro-NASH in obesity. Integrating VFC into clinical practice may enhance risk stratification and facilitate timely interventions for advanced liver disease.